Introduction Hearing aids (HAs) can alleviate hearing loss; however, HA rehabilitation is frequently hampered by delayed diagnosis, suboptimal fitting and lack of systematic follow-up. Although the association between hearing loss and cognitive decline has been identified, evidence from randomised controlled trials remains limited. Addressing these gaps is essential for reducing hearing loss-related experiences and evaluating whether effective HA use could reduce the risk of cognitive decline. Methods and analysis The healthy hearing for healthy ageing study is a proof-of-concept, single-site…
The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
Immune checkpoint inhibitors have revolutionized cancer treatment, helping people with advanced melanoma, lung cancer, bladder cancer, and other cancers live longer, healthier lives. This is the story of how decades of NCI-funded research made these breakthrough immunotherapy drugs possible.
[Sponsored] A five minute survey from MedCity News asks payers what they think of AI and how it is being implemented. Participate today and we will reward you! The post Where Will AI Deployment Benefit Payers the Most? appeared first on MedCity News .
The opioid settlements are a multibillion-dollar windfall with only loose spending suggestions rather than strict requirements. Some people directly affected by the crisis want stronger guardrails. But New York state’s experience highlights the challenge in finding a fiscal watchdog.
Complex computer systems that decide whether people, including the disabled, get Medicaid benefits have a history of errors. Now changes to comply with Trump’s signature tax and domestic policy law are inundating those systems.
Prisoners with severe medical conditions can be granted compassionate release, but without a long-term care facility willing to accept them, many continue to wait in prison as their conditions worsen.
Global hunger declined for a third consecutive year in 2025, demonstrating that progress is possible. However, the improvements remain fragile, unevenly distributed and insufficient to achieve the Sustainable Development Goals by 2030, according to The State of Food Security and Nutrition in the World 2026 (SOFI 2026) report, released on Tuesday by five United Nations specialized agencies.
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for the second time in two months.
Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets pursued by major drugmakers including AstraZeneca, Bayer and Bristol Myers Squibb.
Charlotte, N.C. - Fresh & Ready Foods LLC is recalling a limited number of Sprig & Sprout Spicy Breakfast Burrito and Fresh and Ready Spicy Breakfast Burrito because they may contain undeclared soy. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening a
Dan Malarek is leaving his role as chief executive of Roche’s sequencing subsidiary Foundation Medicine as he takes up the mantle as President and CEO of Roche Diagnostics North America.
In the Original Investigation titled “Epidemiology of Functional Seizures Among Adults Treated at a University Hospital,” published December 29, 2020, the odds ratios reported in the Abstract, Results, and Table 3 were incorrect. An error in the code used to generate the odds ratios resulted in a substantial underestimation of the point estimates. The authors have corrected the code and rerun the relevant analyses. The revised values do not change the direction of the associations or the overall conclusions. The article has been corrected, and the authors have explained how the error occurred…
In the Original Investigation titled “Cognitive Behavioral Therapy for Insomnia in Pain Management for Nonspecific Chronic Spinal Pain: A Randomized Clinical Trial,” published August 9, 2024, there were effect size errors in the Abstract and main article Results, Table 3, Table 4, and Supplement 2. The automation process of the effect size calculation caused the error. The effect sizes have been recalculated and updated. The authors have explained what happened in a Comment, and this article has been corrected.